A Phase 2b, Randomized, Double-blind, Active-controlled Study of Single Dose CVXGA (CVXGA50) Intranasal COVID-19 Vaccine in Adults

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 21 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

09 Dec 2024 Status changed from planning to recruiting, according to a CyanVac media release.
09 Dec 2024 According to a CyanVac media release, Approximately 400 participants initially will be enrolled in sentinel and safety lead-in cohorts. Once an independent Data and Safety Monitoring Board (DSMB) reviews the safety data of the participants, and the Center for the Biomedical Advanced Research and Development Authority (BARDA), provides approval, enrollment of approximately 9,600 additional participants for the second part of the trial will proceed.
17 Jun 2024 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com